Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Breast 1

Conditions

Solitary Fibrous Tumor, Pleural 1Mesothelioma, Malignant 1

Interventions

pembrolizumab 9Specimen Handling 7tislelizumab 6Pemetrexed 6Cisplatin 6Carboplatin 6fludarabine 5atezolizumab 5Interviews as Topic 5Injections 5Cyclophosphamide 5Bevacizumab 5Platinum 4Fluorouracil 4Educational Status 4Biopsy 4Standard of Care 3Practice Guidelines as Topic 3Nivolumab 3Methods 3Magnetic Resonance Spectroscopy 3Early Intervention, Educational 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3sintilimab 2sacituzumab govitecan 2fludarabine phosphate 2X-Rays 2Trastuzumab 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
cediranib × Other solid neoplasm × 30 days × Clear all
NCT01064648 2026-05-29

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
117 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡